A comparative analysis of efficacy and tolerability of such immunomodulating compounds as rebif 22-mcg and copaxone used in the treatment of multiple sclerosis is presented. The analysis was based on the data obtained in the 2-year study of copaxone (145 patients) and rebif 22-mcg (74 patients) therapy carried out in the Neurology Institute, Russian Academy of Medical Sciences.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
rebif 22-mcg
12
comparative analysis
8
22-mcg copaxone
8
analysis rebif
4
copaxone efficacy
4
efficacy multiple
4
multiple sclerosis]
4
sclerosis] comparative
4
analysis efficacy
4
efficacy tolerability
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!